Clinical Trial Update: EPI-743 in Friedreich's Ataxia Point Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial of EPI-743 for Friedreich's Ataxia with point mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• EPI-743

Snippet

Sponsor: University of South Florida | Conditions: Friedreich's Ataxia | Phase 2 | Status: COMPLETED